The study is part of a research programme into mechanisms of asthmatic airway obstruction,
focusing on the role of lipid mediators such as the prostaglandins.
To this end the effect of a non-steroidal anti-inflammatory drug, the selective COX-2
inhibitor etoricoxib, will be evaluated in the allergen challenge setting in twelve subjects
with intermittent allergic asthma. Active treatment for 10 to 13 days will be compared with
an identical study period with no treatment in a cross-over, randomised design. Rising dose
allergen challenges will be performed on three occasions to assess possible changes in
airways responsiveness. Sampling of blood, urine, saliva and sputum will be done to allow for
analyses of the production of prostaglandins and other lipid mediators, of the efficacy of
COX-2 inhibition as well as of regulation of immune cells.
It is hypothesized that inhibition of COX-2 by virtue of inhibition of bronchoprotective
prostaglandin E2 leads to a slightly exaggerated airway response to allergen exposure.